Companies · Biotechnology
Irvine · Biotechnology
Diligence memoA one-page analyst read on Cal-X Stars Business Accelerator, Inc. — recommendation, valuation, rhythm, risks.→Cal-X Stars Business Accelerator, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
Cal-X Stars Business Accelerator, Inc. is one of 4293 Biotechnology companies tracked from Irvine. By capital raised it ranks in the long tail (ahead of 36% of sector peers), and mid-pack by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.
Round size and date are reported; the stage label is inferred from round size (latest is Seed — a $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.
Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 36% of sector peers (real $). Modeled value above 66% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #10 of 122.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Harpoon Medical, Inc. | Seed | $7.8M | $173.2M | 2.59× |
| Admittance Technologies, Inc. | Seed | $3.9M | $173.0M | 2.59× |
| Bell Biosystems, Inc. | Seed | $6.2M | $169.2M | 2.53× |
| Nexstim Plc | Seed | $3.7M | $166.4M | 2.49× |
| Iontera, Inc. | Seed | $16.8M | $164.2M | 2.46× |
| Monteris Medical Inc | Seed | $9.0M | $163.1M | 2.44× |
| Abzena plc | Seed | $4.3M | $160.0M | 2.40× |
| Alkahest, Inc. | Seed | $3.5M | $155.4M | 2.33× |
| ONCoPEP, Inc. | Seed | $12.7M | $153.5M | 2.30× |
| Cal-X Stars Business Accelerator, Inc. this company | Seed | $3.4M | $151.4M | 2.27× |
| QT Holdings Corp. | Seed | $3.8M | $145.9M | 2.19× |
| Insight Genetics, Inc. | Seed | $5.5M | $135.4M | 2.03× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Seed | $1.6M | 2013-11-18 | $7.8M | $68.9M | 90% |
| Seed | $3.2M | 2013-11-18 | $16.0M | $141.9M | 90% |
| Pre-Seed | $387K | 2013-11-18 | $2.2M | $21.4M | 90% |
| Pre-Seed | $517K | 2013-11-18 | $2.9M | $28.5M | 90% |
| Seed | $1.1M | 2013-11-18 | $5.7M | $50.5M | 90% |
| Seed | $2.4M | 2013-11-18 | $11.9M | $105.8M | 90% |
| Seed | $3.4M | 2013-11-18 | $17.0M | $151.4M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Paul Norman | — | 3 other | 2013-11 |
| Howard Leonhardt | — | 2 other | 2013-11 |
| JOHN PAGLIA | — | 2 other | 2013-11 |
| Alex Richardson | — | 1 other | 2013-11 |
| Jeffrey Donofrio | — | 1 other | 2013-11 |
| Ken Evans | — | 1 other | 2013-11 |
| Leslie Miller | — | — | 2013-11 |
| Stuart Richardson | — | — | 2013-11 |
Cal-X Stars Business Accelerator, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Second Heart Assist, Inc. | Biotechnology | Series B | $84.3M | $39.7M | network4 shared operators · same sector |
| Captozyme Inc. | Biotechnology | Seed | $3.4M | $151.0M | same sector · same stage |
| Moleculera Labs, Inc. | Biotechnology | Seed | $3.4M | $131.4M | same sector · same stage |
| Stellar Biotechnologies Inc. | Biotechnology | Seed | $3.4M | $123.6M | same sector · same stage |
| Corino Therapeutics, Inc. | Biotechnology | Seed | $3.5M | $154.3M | same sector · same stage |
| Apostle, Inc. | Biotechnology | Seed | $3.3M | $148.0M | same sector · same stage |
| Heartpoint Global Inc. | Biotechnology | Seed | $3.3M | $147.9M | same sector · same stage |
| Kit Company, Inc. | Biotechnology | Seed | $3.3M | $119.8M | same sector · same stage |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| X-Biomedical Inc. | Biotechnology | Pre-Seed | $23.5M | 83% |
| California Cultured Inc. | Biotechnology | Series A | $48.1M | 82% |
| Constellation Pharmaceuticals Inc | Biotechnology | Series C | $2.7B | 82% |
| Calviri Inc | Biotechnology | Series A | $3.5M | 81% |
| Caladrius Biosciences, Inc. | Biotechnology | Series B | $777.5M | 81% |
| Calysta, Inc. | Biotechnology | Series C | $1.9B | 81% |
| Ascent Industries Corp. | Biotechnology | Pre-Seed | $26.3M | 81% |
| TrackX Technology, Inc. | Biotechnology | Series A | $150.5M | 81% |
See where Cal-X Stars Business Accelerator, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Cal-X Stars Business Accelerator, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.